BI-RADS Category 4a Definition
BI-RADS category 4a indicates a suspicious breast imaging finding with a low probability of malignancy, specifically greater than 2% but less than or equal to 10% likelihood of cancer, warranting tissue biopsy for definitive diagnosis.
Clinical Significance and Malignancy Risk
Category 4a represents the lowest suspicion level within the broader category 4 classification (suspicious abnormality). The finding is not sufficiently benign to allow imaging follow-up alone, but the probability of malignancy remains relatively low 1. This subcategory was created to stratify the wide range of malignancy risk (3-94%) that exists within the general category 4 designation 1.
Evidence-Based Malignancy Rates
Research validates the clinical utility of the 4a subcategory:
- Mammography and ultrasound studies demonstrate positive predictive values (PPV) of 2.5-6% for category 4a lesions, falling within the BI-RADS-specified range 2, 3
- A large retrospective study of 102 category 4a lesions found only 6% were malignant 3
- MRI studies show similar PPV of 1.8-2.5% for category 4a assessments 2, 4
Management Recommendation
Core needle biopsy is the recommended next step for all category 4a lesions 5. While the malignancy probability is low, it exceeds the 2% threshold that separates probably benign (category 3) from suspicious findings requiring tissue diagnosis 1.
Important Clinical Caveats
- Observation alone is not appropriate for category 4a lesions, despite the low malignancy rate
- The subcategory assignment helps inform patient counseling about expected biopsy outcomes
- Concordance between imaging findings and pathology results must be verified after biopsy 5
- If pathology shows benign results that are image-concordant, follow-up imaging at 6-12 month intervals for 1-2 years is recommended before returning to routine screening 5
Common Pitfall
Some studies report higher PPVs for category 4a (34% in one series) 6, suggesting subjectivity in subcategory assignment remains a challenge. Radiologists should apply strict criteria to avoid overcalling lesions as 4a when they may warrant 4b or 4c designation, as this affects patient counseling and clinical decision-making 7.